FDA Approves Cladribine (Mavenclad) for Relapsing MS FDA Approves Cladribine (Mavenclad) for Relapsing MS
The US Food and Drug Administration today approved cladribine for treatment of patients with relapsing multiple sclerosis who have had insufficient response to other agents.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Alert Source Type: news
More News: Brain | Drugs & Pharmacology | Food and Drug Administration (FDA) | Multiple Sclerosis | Neurology | Neurosurgery